MARKET

HSIC

HSIC

Henry Schein
NASDAQ

Real-time Quotes | Nasdaq Last Sale

74.38
+0.84
+1.14%
After Hours: 74.38 0 0.00% 17:00 01/24 EST
OPEN
72.90
PREV CLOSE
73.54
HIGH
74.66
LOW
71.94
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
83.45
52 WEEK LOW
60.70
MARKET CAP
10.31B
P/E (TTM)
16.92
1D
5D
1M
3M
1Y
5Y
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Zacks · 8h ago
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.
Zacks · 10h ago
Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates
Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.
Zacks · 3d ago
Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings
With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.
Zacks · 3d ago
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Zacks · 4d ago
Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.
Zacks · 4d ago
Here's Why You Should Retain Change Healthcare (CHNG) Stock
Change Healthcare (CHNG) continues to benefit from a robust payment accuracy business. However, intense competition remains a woe.
Zacks · 4d ago
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Zacks · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSIC. Analyze the recent business situations of Henry Schein through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
21.43%Buy
50.00%Hold
14.29%Under-perform
0.00%Sell
Analyst Price Target
The average HSIC stock price target is 86.73 with a high estimate of 98.00 and a low estimate of 72.00.
High98.00
Average86.73
Low72.00
Current 74.38
EPS
Actual
Estimate
0.310.620.931.24
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 772
Institutional Holdings: 147.17M
% Owned: 106.12%
Shares Outstanding: 138.67M
TypeInstitutionsShares
Increased
158
6.33M
New
43
1.54M
Decreased
196
6.22M
Sold Out
58
992.22K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.10%
Healthcare Equipment & Supplies
-0.18%
Key Executives
Chairman/Director/Chief Executive Officer
Stanley Bergman
President/Vice Chairman/Director
James Breslawski
Chief Financial Officer/Executive Vice President/Director
Steven Paladino
Corporate Executive
David Brous
Corporate Executive
Brad Connett
Corporate Executive
Rene Willi
Chief Human Resource Officer/Senior Vice President
Lorelei McGlynn
Executive Vice President/Chief Administrative Officer/Director
Gerald Benjamin
Executive Vice President/Director
Mark Mlotek
Senior Vice President/Chief Technology Officer
Christopher Pendergast
Senior Vice President/General Counsel
Kelly Murphy
Senior Vice President/Secretary
Michael Ettinger
Senior Vice President
Jonathan Koch
Senior Vice President
James Mullins
Senior Vice President
Michael Racioppi
Other
Walter Siegel
Secretary
Jennifer Ferrero
Lead Director/Independent Director
Philip Laskawy
Director
Scott Serota
Independent Director
Mohamad Ali
Independent Director
Barry Alperin
Independent Director
Deborah Derby
Independent Director
Joseph Herring
Independent Director
Kurt Kuehn
Independent Director
Anne Margulies
Independent Director
Carol Raphael
Independent Director
Elizabeth Rekow
Independent Director
Bradley Sheares
No Data
About HSIC
Henry Schein, Inc. is a provider of healthcare products and services primarily to office-based dental and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The technology and value-added services segment provides software, technology and other value-added services to healthcare practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners. The Company provides its services to dental practitioners and laboratories, and physician practices, as well as government and institutional healthcare clinics.

Webull offers kinds of Henry Schein, Inc. stock information, including NASDAQ:HSIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSIC stock methods without spending real money on the virtual paper trading platform.